Ressources

Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.

 

 
This Rapid Response report aims to review the effectiveness of the use of telehealth-delivered OAT compared to standard OAT.
Lit review | 2018
Clinical guidance, Evidence base, Policy/Regulatory, Safer supply, About prescribers
Users of poppy seed tea (PST) can consume several hundred morphine milligram equivalents per day, and opioid dependence from PST use can develop.
Original research | 2021
Withdrawal, Clinical guidance, Hesitancy of prescribers , About prescribers, Outcomes, Chronic pain, Substitution/OAT, Stigma
Despite a current lack of direct evidence, this document has been created to urgently combat overdose deaths. It is informed by existing research and based out of expert opinion.
Guidelines | 2020
Mortality, Clinical guidance, Harm reduction, Safer supply, About prescribers, Transitions in care/treatment, Injecting drugs, Diversion
Quebec safe supply clinical guidance for prescribers
Guidelines | 2020
Overdose, Clinical guidance, Harm reduction, Safer supply, About prescribers, Stimulants, Substitution/OAT, Transitions in care/treatment, Injecting drugs
Guide or handbook | 2020
Clinical guidance, Harm reduction, Illegal drugs, Injecting drugs
Slide deck | 2021
Clinical guidance, About prescribers, Small/medium cities
FBT is indicated for the management of breakthrough pain (a transient flare of pain on a background of chronic pain otherwise controlled by treatment with opioids) in patients with cancer who are alre
Original research | 2008
Clinical guidance, About prescribers, Chronic pain
This review describes the diagnosis, prevalence, course and management of cannabis withdrawal and highlights opportunities for future clinical research.
Lit review | 2021
Withdrawal, Clinical guidance
Assess whether 4x100μg fentanyl buccal tablets had the same biological effect as 1 400μg tablet
Original research | 2006
Clinical guidance, About prescribers
This study reports the outcomes of the B-Team (Buprenorphine-Team), a hospitalist-led interprofessional program created to identify hospitalized patients with OUD, initiate buprenorphine in the inpati
Original research | 2021
Clinical guidance, Evidence base, Wrap-around services, About prescribers, Outcomes, Substitution/OAT, Transitions in care/treatment, Hospitals
Slide deck | 2019
Clinical guidance, Harm reduction, About prescribers, Illegal drugs, Hospitals
Commentary | 2021
Withdrawal, Clinical guidance, Policy/Regulatory, About prescribers, Illegal drugs, Stigma, Hospitals
The clinical guideline was developed to provide key clinical recommendations, as well as clinical guidance on the provision of iOAT.
Guidelines | 2019
Clinical guidance, Policy/Regulatory, Safer supply, About prescribers, Illegal drugs, Stimulants, Transitions in care/treatment, Injecting drugs
Archived webinar | various
Clinical guidance, Policy/Regulatory, Safer supply, About prescribers, Injecting drugs
Archived webinar | 2020
Clinical guidance, Harm reduction, Safer supply, About pharmacists, About prescribers, Housing
Guidelines | 2017
Clinical guidance, Evidence base, Policy/Regulatory, About prescribers
Guidelines | 2023
Clinical guidance, Policy/Regulatory, About prescribers
We discuss accumulated evidence (Box 1) on social interventions and provide an overview of common primary care–based interventions (Table 1), highlighting their strengths, limitations and feasibility
Lit review | 2021
Clinical guidance, Wrap-around services, Equity, About prescribers, Social services

BC safe suply interim guidance for safe supply/COVID-19 risk mitigation during the pandemic

Guidelines | 2022
Overdose, Clinical guidance, Harm reduction, Safer supply, About prescribers, Rural/remote, Substitution/OAT, Carries/take-home doses

Affiner votre recherche

Mots clés
Format
Région